SCHEMBL8725926

SCHEMBL8725926

CC(=O)c1cccc(C(=O)Nc2ccc3scc(C4=CCN5CCCCC5CC4)c3c2)c1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.37
L3MBTL3 Q96JM7 1/20 0.37
MAPT P10636 5/20 0.37
TP53 P04637 3/20 0.37
LMNA P02545 2/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
ALDH1A1 P00352 3/20 0.36
POLB P06746 2/20 0.36
RXFP1 Q9HBX9 1/20 0.36
KMT2A Q03164 4/20 0.36
MEN1 O00255 3/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
MAPK1 P28482 1/20 0.35
CREBBP Q92793 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8720711 0.92 TP53 (0.44) TDP1MAPTTP53LMNANPC1
SCHEMBL8720823 0.91 TDP1 (0.39) TDP1L3MBTL1L3MBTL3MAPTTP53
SCHEMBL8723604 0.91 TDP1 (0.39) TDP1L3MBTL1L3MBTL3MAPTTP53
SCHEMBL8724153 0.89 POLB (0.41) TDP1L3MBTL1MAPTLMNANPC1
SCHEMBL8721851 0.88 TDP1 (0.38) TDP1L3MBTL1L3MBTL3MAPTTP53
SCHEMBL8720693 0.87 NPC1 (0.44) TDP1MAPTLMNANPC1RAB9A
SCHEMBL8721285 0.87 KCNQ3 (0.40) MAPTTP53LMNANPC1RAB9A
SCHEMBL8720679 0.87 MAPK14 (0.38) TDP1L3MBTL1L3MBTL3MAPTTP53
SCHEMBL8724021 0.87 HTR1F (0.40) MAPTTP53NPC1RAB9AHTT
SCHEMBL8723878 0.86 NR1H4 (0.46) TDP1L3MBTL1MAPTLMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ LP (CA) 2026-05-07 US disclosed
EP-0875513-A1 Substituted heteroaromatic 5-HT 1F agonists ELI LILLY AND COMPANY (US) 1998-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS HTR1F, HTR1A, HTR1D TDP1 1651/4885L3MBTL1 415/4885L3MBTL3 674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.